Cited by 366Psychedelics and Drug StudiesParanormal Experiences and BeliefsReligion, Spirituality, and Psychology

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Open access
Barrett, Frederick S, Bradstreet, Matthew P, Leoutsakos, Jeannie-Marie S, Johnson, Matthew W, Griffiths, Roland R·2016·Journal of Psychopharmacology

Abstract

Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire. The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression. The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881116678781

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

11 of the 73 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. Frecska E Luna LE 2006 The adverse effects of hallucinogens from intramural perspective Neuropsychopharmacologia Hungarica: A Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology 8 4 189 200 17211054
  2. Metzner R Litwin G Weil G 1965 The relation of expectation and mood to psilocybin reactions: A questionnaire study Psychedelic Review 5 3 3-39
  3. Pahnke WN Kurland AA Goodman LE Richards WA 1969 LSD-assisted psychotherapy with terminal cancer patients Current Psychiatric Therapies 9 144 152 5348915
  4. Panksepp J 1998 Affective neuroscience: The foundations of human and animal emotions New York Oxford University Press

Cited by

Sorted by citations

Authors
Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R.
Affiliations
Johns Hopkins University (US)
Corresponding author
Barrett, Frederick S
Venue
Journal of Psychopharmacology
Published
2016-11-19
Volume
30
Issue
12
Pages
1279-1295
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2549202270
Cited by
366
References
73
Citations by year
2026: 43 · 2025: 77 · 2024: 93 · 2023: 41 · 2022: 39 · 2021: 32 · 2020: 15 · 2019: 10 · 2018: 13 · 2017: 3
FWCI
11.60
Type
journal article
Language
en
Open access
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute on Drug Abuse (R01DA003889, T32DA007209)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
  • Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords
psilocybin, challenging experiences, bad trips, questionnaire validation, grief, fear, death, paranoia, isolation, physical distress, altered states of consciousness, meaningfulness, spiritual meaning, well-being
MeSH terms
Adult, Affect, Agaricales, Anxiety, Depression, Emotions, Female, Hallucinogens, Humans, Male, Psilocybin, Surveys and Questionnaires

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review